An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease. (SP512OL)

UCB

Status and phase: Completed; Phase 3

Conditions: Early-Stage Parkinson's Disease

Treatments: Drug: Rotigotine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00594165

SP0702

SP512OL

Details and patient eligibility

About

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.

Full description

This is the open-label extension to the randomized, double-blind, placebo-controlled SP512 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease.

Enrollment: 217 patients

Sex: All

Ages: 31+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who have completed six months of maintenance treatment in the SP512 double-blind trial

Exclusion criteria

• Subjects who had an ongoing serious adverse event from SP512 double-blind trial that was assessed as related to study medication

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

217 participants in 1 patient group

Rotigotine

Experimental group

Description:

Rotigotine

Treatment:

Drug: Rotigotine